Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OncoCyte Corp OCX

Healthcare Biotechnology
Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict... see more

Recent & Breaking News (NDAQ:OCX)

Oncocyte Reports First Quarter 2024 Financial Results

GlobeNewswire 2 days ago

Oncocyte to Announce First Quarter 2024 Financial Results

GlobeNewswire 4 days ago

Oncocyte Reports Full Year 2023 Financial Results

GlobeNewswire April 12, 2024

Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

GlobeNewswire April 11, 2024

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

GlobeNewswire April 11, 2024

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire April 9, 2024

Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

GlobeNewswire January 16, 2024

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

GlobeNewswire December 6, 2023

Oncocyte Reports Third Quarter 2023 Financial Results

GlobeNewswire November 9, 2023

Oncocyte to Announce Third Quarter 2023 Financial Results

GlobeNewswire November 3, 2023

Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Accesswire September 18, 2023

Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Accesswire September 6, 2023

Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Accesswire August 28, 2023

Oncocyte Reports Second Quarter 2023 Financial Results

Accesswire August 10, 2023

Oncocyte Regains Compliance With Nasdaq Listing Requirements

Accesswire August 9, 2023

Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference

Accesswire August 8, 2023

Oncocyte To Announce Second Quarter 2023 Financial Results

Accesswire August 3, 2023

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

GlobeNewswire July 25, 2023

Oncocyte Announces 1-For-20 Reverse Stock Split

GlobeNewswire July 24, 2023

Oncocyte Begins Manufacturing Transplant Blood Test

GlobeNewswire June 27, 2023